Unformatted text preview: affected by NSAIDs, their interaction with ancillary risk factors, and how to optimise management in subgroups, remain poorly understood. In this article, strategies for subgroups that take account of non-specific gastrointestinal risks, minimisation of residual risk, and the importance of non-gastrointestinal toxicity are suggested, and areas for research identified. PMCID: PMC1773617 PMID: 12631678 [PubMed - indexed for MEDLINE]...
View Full Document
- Spring '09
- Gastroenterology, Paracetamol, Non-steroidal anti-inflammatory drug, Cyclooxygenase